Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.24 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 1 stopped | 0.60 |
| literature PubMed | 1 Parkinson's papers of 138 | 0.91 |
| pathways Reactome | 1 pathway; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 12326
Sealed predictions
- SUCLA2 in dopamine neurons, braak-0.27 (p 0.474) → +0.49 (p 0.181)receipt 12333
Swarm cases
receipt 12333: SUCLA2 in dopamine neurons, braak
- power
- full sample +0.09 (p 0.709, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.18 (p 0.465, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.439, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.23, sign flips 2; without severely affected donors +0.09 (p 0.709, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SUCLA2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts